Cotara continues to perform well in trial

05/31/2009 | Medical News Today

Cotara, a targeted monoclonal antibody-based treatment developed by Peregrine Pharmaceuticals, has continued to show efficacy against a lethal form of brain cancer, called glioblastoma multiforme, in a Phase II trial. Trial data showed that the drug candidate has the capacity to target solid tumors and that it has a safe profile. Interim data from a dose confirmation and dosimetry study of the therapy will be presented at the SNM meeting in June.

View Full Article in:

Medical News Today

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ
Actuary
Meridian Health Plan
Detroit, MI
Assistant Vice President - Dental Director
MetLife
Bridgewater, NJ